New Therapeutic Approaches for Heart Failure with Preserved Ejection Fraction
DOI:
https://doi.org/10.63688/9xw9rh45Keywords:
Heart failure, preserved ejection fraction, therapeuticsAbstract
Introduction: Heart failure with preserved ejection fraction constitutes a complex and increasingly prevalent cardiovascular syndrome in the general population, associated with high morbidity and mortality and a historically limited therapeutic management that continues in constant clinical evolution.
Objective: Synthesize current scientific evidence regarding new therapeutic approaches applied to the comprehensive management of heart failure with preserved ejection fraction.
Methods: A comprehensive narrative literature review was conducted. Initially, 180 documents were identified across specialized scientific databases, and after applying rigorous selection criteria, 11 relevant studies were included for final analysis.
Results: Sodium-glucose cotransporter-2 inhibitors demonstrated consistent benefits by significantly reducing hospitalizations and cardiovascular events. Finerenone presented highly favorable outcomes against heart failure worsening. Meanwhile, glucagon-like peptide-1 receptor agonists showed substantial clinical improvements in patients with comorbid obesity, whereas several other pharmacological strategies remain under active investigation.
Conclusions: Emerging pharmacological therapies promote a more precise and individualized clinical management, although additional studies are required to conclusively establish their long-term benefits.
Downloads
References
Asbeutah, A. A., & Goldberger, Z. D. (2024). Novel therapies for the treatment of cardiovascular disease. Medical Clinics of North America, 108(5), 953–964. https://doi.org/10.1016/j.mcna.2024.03.003
Brandner, J., Tessitore, E., Guijarro, D., & Valiton, V. (2024). Avancées dans le diagnostic et traitement de l’insuffisance cardiaque à fraction d’éjection préservée. Revue Médicale Suisse, 20(875), 1005–1009. https://doi.org/10.53738/REVMED.2024.20.875.1005
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Chiang, C.-E., Linssen, G. C. M., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., von Lewinski, D., Lay-Flurrie, J., Scalise, A., Rohwedder, K., Desai, A. S., Lam, C. S. P., Senni, M., Shah, S. J., Zannad, F., Pitt, B., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2025). Finerenone according to frailty in heart failure: A prespecified analysis of the FINEARTS-HF randomized clinical trial. JAMA Cardiology, 10(8), 829–840. https://doi.org/10.1001/jamacardio.2025.1775
Campbell, P., Rutten, F. H., Lee, M. M., Hawkins, N. H., & Petrie, M. C. (2024). Heart failure with preserved ejection fraction: Everything the clinician needs to know. The Lancet, 403(10431), 1083–1092. https://doi.org/10.1016/S0140-6736(23)02756-3
Chen, X., Huang, M., Chen, Y., Xu, H., & Wu, M. (2025). Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: Current understanding and future prospects. Heart Failure Reviews, 30(1), 191–208. https://doi.org/10.1007/s10741-024-10455-1
Chopra, V., Khan, M. S., Abdelhamid, M., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D., Burgos, L. M., Butler, J., Costanzo, M. R., Damasceno, A., Ezekowitz, J. A., Hameed, I., Harikrishnan, S., Jaarsma, T., Lala, A., ... Zieroth, S. (2025). iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025. Heart, Lung and Circulation, 34(7), e55–e82. https://doi.org/10.1016/j.hlc.2025.05.094
Desai, N., Olewinska, E., Famulska, A., Remuzat, C., Francois, C., & Folkerts, K. (2024). Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Failure Reviews, 29(3), 631–662. https://doi.org/10.1007/s10741-024-10385-y
Ezhumalai, B., Modi, R., Panchanatham, M., & Kaliyamoorthy, D. (2024). The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review. Indian Heart Journal, 76(4), 229–239. https://doi.org/10.1016/j.ihj.2024.07.005
Feng, W., & Ren, M. (2023). Recent advances in the study and treatment of heart failure with preserved ejection fraction. Chinese Journal of Arteriosclerosis, 31(12), 1073–1080. https://doi.org/10.20039/j.cnki.1007-3949.2023.12.009
Greene, S. J., Bauersachs, J., Brugts, J. J., Ezekowitz, J. A., Lam, C. S. P., Lund, L. H., Ponikowski, P., Voors, A. A., Zannad, F., Zieroth, S., & Butler, J. (2023). Worsening heart failure: Nomenclature, epidemiology, and future directions: JACC review topic of the week. Journal of the American College of Cardiology, 81(4), 413–424. https://doi.org/10.1016/j.jacc.2022.11.023
Joury, A., Gupta, T., & Krim, S. R. (2022). New concepts in heart failure with preserved ejection fraction and hypertension. Current Opinion in Cardiology, 37(5), 424–430. https://doi.org/10.1097/HCO.0000000000000981
Khan, M. S., Shahid, I., Bennis, A., Rakisheva, A., Metra, M., & Butler, J. (2024). Global epidemiology of heart failure. Nature Reviews Cardiology, 21(10), 717–734. https://doi.org/10.1038/s41569-024-01046-6
Pugliese, N. R., Pellicori, P., Filidei, F., De Biase, N., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2022). Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: Implications for future interventions. Cardiovascular Research, 118(18), 3536–3555. https://doi.org/10.1093/cvr/cvac133
Sauer, A. J., Ter Maaten, J. M., & Savarese, G. (2026). Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF. ESC Heart Failure, 13(2), xvag056. https://doi.org/10.1093/eschf/xvag056
Stoicescu, L., Crişan, D., Morgovan, C., Avram, L., & Ghibu, S. (2024). Heart failure with preserved ejection fraction: The pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. International Journal of Molecular Sciences, 25(2), 794. https://doi.org/10.3390/ijms25020794
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Luis Guillermo Mendoza Rodriguez, Daiana Stefanny Morán Higuera, Jose Miguel Bustos Ramon, Allyson Madeline Barrera Vásquez, Jhoselyn Nicole Coque Tonato (Autor/a)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Los artículos publicados en la revista se distribuyen bajo la licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esta licencia permite a terceros descargar, copiar, distribuir, adaptar y reutilizar una obra, incluso con fines comerciales, siempre que se otorgue el crédito adecuado al autor original.
